Illumina Completes SomaLogic Acquisition, Expands Proteomics Capabilities
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Illumina ( (ILMN) ).
On January 30, 2026, Illumina completed its previously announced acquisition of SomaLogic and related aptamer-based and functional proteomics assets from Standard BioTools for $350 million in cash at closing, plus up to $75 million in performance-based milestone payments and royalties funded from cash on hand. The deal folds SomaLogic’s SomaScan proteomics assay, SomaSignal tests and other proteomics technologies into Illumina’s next-generation sequencing ecosystem, including DRAGEN software and Illumina Connected Multiomics, significantly deepening its capabilities in proteomics and multiomics and positioning the company for growth in the expanding proteomics market while committing to continuity of service and support for existing SomaLogic customers and partners.
The most recent analyst rating on (ILMN) stock is a Buy with a $170.00 price target. To see the full list of analyst forecasts on Illumina stock, see the ILMN Stock Forecast page.
Spark’s Take on ILMN Stock
According to Spark, TipRanks’ AI Analyst, ILMN is a Neutral.
ILMN scores well on recovering fundamentals and a strong technical uptrend, supported by an earnings call with upside execution and raised outlook driven by clinical/NovaSeq X momentum. The score is held back by weaker cash-flow trends, higher leverage risk, and a relatively expensive valuation, with some added execution uncertainty from recent leadership shifts.
To see Spark’s full report on ILMN stock, click here.
More about Illumina
Illumina is a global leader in DNA sequencing and array-based technologies, providing next-generation sequencing platforms, software and consumables to research, clinical and applied markets. Its products support applications across life sciences, oncology, reproductive health, agriculture and other emerging segments, underpinning the company’s strategy to expand from genomics into broader multiomics solutions.
Average Trading Volume: 1,867,245
Technical Sentiment Signal: Hold
Current Market Cap: $22.9B
See more insights into ILMN stock on TipRanks’ Stock Analysis page.
